SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2021 / Oncology Pharma Inc. (OTC PINK: ONPH) According to the previously announced news release, Oncology Pharma, Inc. (the “Company”) has selected the services of DBBMcKennon, LLC, a PCAOB certified accounting firm. The company has engaged the company to conduct a review of its financial data to comply with SEC reporting standards with respect to its intended NASDAQ capital market listing. The management team has worked diligently to bring the company into an environment where it can support the dynamism, growth and movement of the company with an eye to the future.
DBBMcKennon is a full-service, PCAOB Registered Certified Public Accounting company providing auditing, tax and advisory services to individuals and corporations through its offices in Newport Beach, San Diego and Santa Monica, CA.
A company spokesman said: “We look forward to working with DBBMcKennon and the prospect of an uplisting.” More will follow as soon as important events are available.
ABOUT ONCOLOGY PHARMA, INC.
ONCOLOGY PHARMA, INC. (OTC PINK: ONPH) (the “Company”) is currently engaged in the research and development of therapeutics for oncology and is proud to have a world-class advisory board that keeps the Company at the forefront of developing cancer research, biotechnology and healthcare.
Certain of the matters discussed in this release contain forward-looking statements that involve material risks and uncertainties in the company’s business that could cause actual results to differ materially from those anticipated in the statements herein. These risks and uncertainties include risks associated with licensing agreements and joint ventures, including the need to negotiate the final arrangements for the relationships; possible lack of expected benefits from business relationships; and the cost of providing funding for these relationships. Other risks and uncertainties relating to the company include, but are not limited to, current negative operating cash flows and the need for additional funding to fund our operating plan; the terms of any further funding, which may be highly dilutive and contain onerous terms; unexpected costs and operating shortfalls and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technology and other factors that may affect further market uptake; unfavorable economic conditions; adverse results of legal proceedings; the volatility of our operating results and financial condition; Inability to attract or retain qualified management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to potentially license from other patents and patent applications required for product development; the company’s ability to execute its long-term business plan for various uses of its technology; the company’s ability to enter into agreements with any necessary marketing and / or sales partners, as well as with strategic partners or joint venture partners; the effects of competition; Obtaining and maintaining all necessary regulatory approvals for applications of the Company’s technology; Management of growth; and other risks and uncertainties. This is not a solicitation to buy or sell any securities and is not intended to be an analysis of the company’s financial condition.
For more information, please contact Oncology Pharma at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
SOURCE: Oncology Pharma Inc.
View source version on accesswire.com: